Quantitative analysis of the expression of molecules belonging to the IRS on T and NK lymphocytes from patients with PNH
Patient no. . | CD3+ KIR2D+, cell/μL . | CD3– KIR2D+, cell/μL . | CD3+ KIR2D+, % of T cells . | CD3+CLIR+, cell/μL . | CD3–CLIR+, cell/μL . | CD3+CLIR+, % of T cells . |
|---|---|---|---|---|---|---|
| PNH1 | ||||||
| Sample 5 | 98 | 91.6 | 2.9 | – | – | – |
| Sample 3 | – | – | – | 31.3 | 27.3 | 3.1 |
| PNH2 | ||||||
| Sample 2 | 195 | 69 | 20.6 | – | – | – |
| PNH3 | ||||||
| Sample 5 | 51 | 30.6 | 3.7 | – | – | – |
| Sample 3 | – | – | – | 64 | 42 | 4.8 |
| PNH4 | ||||||
| Sample 1 | 55 | 10 | 9.2 | – | – | – |
| PNH5 | ||||||
| Sample 2 | 52.5 | 206 | 3.8 | – | – | – |
| PNH6 | ||||||
| Sample 4 | 70.2 | 10 | 8.3 | – | – | – |
| Sample 2 | – | – | – | 115.5 | 9.5 | 12.7 |
| PNH7 | ||||||
| Sample 4 | 61.8 | 80.3 | 5.8 | – | – | – |
| Sample 2 | – | – | – | 112.5 | 87 | 8.4 |
| PNH8 | ||||||
| Sample 2 | 57.5 | 69.5 | 3.8 | – | – | – |
| PNH9 | ||||||
| Sample 3 | 71.3 | 174.7 | 5 | – | – | – |
| Sample 1 | – | – | – | 87 | 204 | 6.9 |
| PNH10 | ||||||
| Sample 1 | 29 | 10 | 2.9 | – | – | – |
| PNH11 | ||||||
| Sample 4 | 151.3 | 111.8 | 15.3 | – | – | – |
| Sample 3 | – | – | – | 177.3 | 73.0 | 17.0 |
| PNH12 | ||||||
| Sample 1 | 87 | 34 | 9.4 | 67 | 24 | 7.2 |
| PNH13 | ||||||
| Sample 1 | 31 | 27 | 2.6 | 94 | 56 | 7.9 |
| Mean ± SD (range) | 81.8 ± 47.0 (31-195) | 76.2 ± 62.7 (10-206) | 7.5 ± 5.5 (2.6-20.6) | 96.3 ± 43.7 (31.3-177.3) | 65.4 ± 61.7 (9.5-204.0) | 8.5 ± 4.4 (3.1-17.0) |
| Healthy controls* | ||||||
| Mean ± SD (range) | 63 ± 36 (19-171) | 192 ± 155 (8-690) | 4.3 ± 2.4 (1.3-11.4) | 102 ± 71 (15-309) | 214 ± 155 (9-666) | 6.8 ± 4.7 (1.0-20.6) |
Patient no. . | CD3+ KIR2D+, cell/μL . | CD3– KIR2D+, cell/μL . | CD3+ KIR2D+, % of T cells . | CD3+CLIR+, cell/μL . | CD3–CLIR+, cell/μL . | CD3+CLIR+, % of T cells . |
|---|---|---|---|---|---|---|
| PNH1 | ||||||
| Sample 5 | 98 | 91.6 | 2.9 | – | – | – |
| Sample 3 | – | – | – | 31.3 | 27.3 | 3.1 |
| PNH2 | ||||||
| Sample 2 | 195 | 69 | 20.6 | – | – | – |
| PNH3 | ||||||
| Sample 5 | 51 | 30.6 | 3.7 | – | – | – |
| Sample 3 | – | – | – | 64 | 42 | 4.8 |
| PNH4 | ||||||
| Sample 1 | 55 | 10 | 9.2 | – | – | – |
| PNH5 | ||||||
| Sample 2 | 52.5 | 206 | 3.8 | – | – | – |
| PNH6 | ||||||
| Sample 4 | 70.2 | 10 | 8.3 | – | – | – |
| Sample 2 | – | – | – | 115.5 | 9.5 | 12.7 |
| PNH7 | ||||||
| Sample 4 | 61.8 | 80.3 | 5.8 | – | – | – |
| Sample 2 | – | – | – | 112.5 | 87 | 8.4 |
| PNH8 | ||||||
| Sample 2 | 57.5 | 69.5 | 3.8 | – | – | – |
| PNH9 | ||||||
| Sample 3 | 71.3 | 174.7 | 5 | – | – | – |
| Sample 1 | – | – | – | 87 | 204 | 6.9 |
| PNH10 | ||||||
| Sample 1 | 29 | 10 | 2.9 | – | – | – |
| PNH11 | ||||||
| Sample 4 | 151.3 | 111.8 | 15.3 | – | – | – |
| Sample 3 | – | – | – | 177.3 | 73.0 | 17.0 |
| PNH12 | ||||||
| Sample 1 | 87 | 34 | 9.4 | 67 | 24 | 7.2 |
| PNH13 | ||||||
| Sample 1 | 31 | 27 | 2.6 | 94 | 56 | 7.9 |
| Mean ± SD (range) | 81.8 ± 47.0 (31-195) | 76.2 ± 62.7 (10-206) | 7.5 ± 5.5 (2.6-20.6) | 96.3 ± 43.7 (31.3-177.3) | 65.4 ± 61.7 (9.5-204.0) | 8.5 ± 4.4 (3.1-17.0) |
| Healthy controls* | ||||||
| Mean ± SD (range) | 63 ± 36 (19-171) | 192 ± 155 (8-690) | 4.3 ± 2.4 (1.3-11.4) | 102 ± 71 (15-309) | 214 ± 155 (9-666) | 6.8 ± 4.7 (1.0-20.6) |
Peripheral-blood lymphocytes were isolated from the indicated patients. Samples of blood were collected at about 3 months from one to another during the follow-up; the sample number indicates the number of the blood collection. Samples were stained with anti-CD3 mAb and anti-panKIR2D mAb (NKVFS1) or anti-CLIR mAb followed by isotype-specific antimouse antiserum. At least 10 000 events for each sample were analyzed on a FACSort (Becton Dickinson). Percent of CD3+ T lymphocytes that are KIR2D+ or CLIR+ is also shown.
– indicates that the sample was not stained with the indicated antibody combination.
For healthy controls, n = 38 for CD3/KIR2D staining, and n = 17 for CD3/CLIR staining